Pramlintide
Pramlintide (Symlin) is the synthetic non-aggregating amylin analogue with three proline substitutions. FDA-approved as adjunct to insulin. Reduces postprandial glucose ~30%, suppresses glucagon, and produces 1-2 kg weight loss.
Community Rating
No ratings yet
Compound Profile
Pramlintide
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Pramlintide is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Reduces postprandial glucose excursions by approximately 30% when added to insulin therapy
- Suppresses prandial glucagon secretion — complementary mechanism to insulin's primary action
- Slows gastric emptying rate — smooths glucose absorption curve
- Pramlintide is not FDA-approved for human use. FDA-approved prescription drug (Symlin, AstraZeneca). Indicated as adjunct to mealtime insulin in T1D and insulin-using T2D.
Research At a Glance
- Reduces postprandial glucose excursions by approximately 30% when added to insulin therapy
- Suppresses prandial glucagon secretion — complementary mechanism to insulin's primary action
- Slows gastric emptying rate — smooths glucose absorption curve
- Reduces daily insulin requirement by approximately 10-15% in type 1 diabetes
In Plain English
Simple summaryPramlintide (Symlin) is a synthetic analogue of amylin -- the peptide your pancreatic beta cells co-secrete with insulin at every meal. Like insulin, amylin production is destroyed in Type 1 diabetes and severely impaired in Type 2. Pramlintide was FDA-approved in 2005 to replace that missing signal: it slows gastric emptying, suppresses postprandial glucagon release, and signals satiety to the brain through the area postrema. In clinical trials, it reduced HbA1c by 0.5-0.7%, reduced postprandial glucose spikes substantially, and produced 1-2 kg weight loss over 6 months -- modest numbers, but this was on top of existing insulin therapy. Its primary role in Type 1 diabetes is smoothing out the post-meal glucose spikes that even optimized insulin regimens struggle to control.
- Reduces postprandial glucose excursions by approximately 30% when added to insulin therapy
- Suppresses prandial glucagon secretion — complementary mechanism to insulin's primary action
- Slows gastric emptying rate — smooths glucose absorption curve
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Pramlintide?
Tap any underlined term for an instant definition.
Pramlintide (brand name: Symlin) is a synthetic analogue of human amylin (islet amyloid polypeptide, IAPP) engineered to replicate amylin's pharmacological effects without the aggregation liability of the native peptide. It was developed by Amylin Pharmaceuticals and received FDA approval in 2005 as the first non-insulin drug approved to treat type 1 diabetes in over three decades.
The key structural modification is three alanine-to-proline substitutions at positions 25, 28, and 29, mimicking the proline-rich sequence found in rat IAPP. Proline residues disrupt alpha-helical structure and beta-sheet formation, preventing the fibril aggregation that makes human amylin clinically unusable. Pramlintide retains full amylin receptor (AMY1/AMY3) binding and biological activity.
**Mechanism of action:** 1. AMY1/AMY3 receptor activation (calcitonin receptor + RAMP1/3) in area postrema and brainstem 2. → Suppresses postprandial glucagon secretion (~40-60% reduction) 3. → Slows gastric emptying (reduces rate of glucose absorption) 4. → Central satiety signaling via NTS/arcuate nucleus 5. Together: blunts postprandial glucose excursions by approximately 30%
**Clinical trial results:** - PRALAN trial: Pramlintide + insulin in T1D reduced HbA1c by 0.39% vs placebo, with weight loss of 1.4 kg over 52 weeks - T2D trials: 0.4% HbA1c reduction + 2.0 kg weight loss vs placebo at 120 mcg TID - The hypoglycemia risk is real — initiation requires 50% prandial insulin dose reduction
Pramlintide represents the clinical proof-of-concept that the amylin axis is a tractable therapeutic target. Next-generation amylin/GLP-1 co-agonists (cagrilintide + semaglutide, LY3209590) are in late-stage development and show substantially greater weight loss than either hormone class alone.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Pramlintide. See all Metabolic & Weight peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Pramlintide (Symlin) is dosed immediately before major meals (≥250 kcal or ≥30g CHO):
Type 1 Diabetes protocol: - Start: 15 mcg SC before meals - Titrate: 15 mcg increments every 3-7 days if tolerated - Target: 30-60 mcg before meals - Reduce mealtime insulin dose by 50% at initiation
Type 2 Diabetes protocol: - Start: 60 mcg SC before meals - Titrate to: 120 mcg if tolerated (after 3-7 days) - Reduce mealtime insulin dose by 50% at initiation
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Inject subcutaneously in the abdomen or thigh immediately before each major meal. Use a separate injection site from insulin. Do not mix with insulin. Use 1 mL insulin-calibrated syringe (50 mcg/mL concentration).
What the research doesn't show
Pramlintide's modest commercial uptake tells the story: the 3x daily injection burden on top of existing insulin regimens is significant, and the 1-2 kg weight loss was underwhelming to patients expecting more. It works mechanistically -- the postprandial glucose data is solid -- but the clinical experience package never caught on outside a niche of highly motivated Type 1 patients seeking tighter control.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Pramlintide, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Pramlintide has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: reduces postprandial glucose excursions by approximately 30% when added to insulin therapy.
The most commonly reported side effect in research subjects is nausea in approximately 30-50% of patients — dose-dependent, improves with gradual up-titration. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
Cagrilintide is the long-acting amylin analogue designed for once-weekly use alongside semaglutide. Pramlintide requires injection at every meal (three times daily), which is its primary compliance limitation. The mechanism is the same; the dosing frequency is what separates them clinically. For understanding what amylin biology does in humans, pramlintide's decade-long clinical record is the evidence base.
Compare Pramlintide side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.